In 2013 there were ~200 million clinical cases of malaria, causing ~600,000 deaths. All antimalarial drugs are now associated with malaria parasite resistance. Thus, new therapies are urgently needed, including new drugs to prevent this disease. We have made the exciting discovery that an existing antimalarial drug can kill malaria parasites in a unique, previously unknown, manner. Here, we will investigate how this occurs and develop new drug candidates for malaria prevention.
Genomic and molecular characterisation of a novel Australian leishmania pathogen. Leishmaniasis is the second most serious protozoal disease after malaria. This project will help characterise the first Leishmania species identified in Australia providing molecular tools to monitor the pathogen and a detailed assessment of any potential risk to human health. Comparative analysis with more pathogenic species will help identify genes and mechanisms that determine the progression of human disease le ....Genomic and molecular characterisation of a novel Australian leishmania pathogen. Leishmaniasis is the second most serious protozoal disease after malaria. This project will help characterise the first Leishmania species identified in Australia providing molecular tools to monitor the pathogen and a detailed assessment of any potential risk to human health. Comparative analysis with more pathogenic species will help identify genes and mechanisms that determine the progression of human disease leading to the potential identification of new drug and vaccine targets. The methodologies and expertise developed will be used will be available to other research groups working on infectious diseases.Read moreRead less
Are alternative histones important regulators of transcription in Plasmodium falciparum? Malaria parasites depend on tightly controlled expression of their genes for maintaining infection and causing disease. The project will identify mechanisms of gene control used by parasites; these mechanisms may provide targets for malaria therapies.
Investigating why malaria parasites have a unique translocon. This project aims to explore the mechanism that enables malaria parasites to thrive in their host cells. Parasites that cause the disease malaria reside inside erythrocytes, a very basic cell that lacks a vesicular trafficking pathway. To survive and thrive in this environment, the parasite has evolved a completely unique cell biological phenomenon termed PTEX to transport its proteins into the host cell. The aim of this project is to ....Investigating why malaria parasites have a unique translocon. This project aims to explore the mechanism that enables malaria parasites to thrive in their host cells. Parasites that cause the disease malaria reside inside erythrocytes, a very basic cell that lacks a vesicular trafficking pathway. To survive and thrive in this environment, the parasite has evolved a completely unique cell biological phenomenon termed PTEX to transport its proteins into the host cell. The aim of this project is to determine how this novel PTEX machinery exports proteins into erythrocytes and whether PTEX is also required for parasite survival during the initial stages of a host infection when malaria reside in hepatocytes.Read moreRead less
Structural and functional characterisation of compounds that inhibit the malarial aminopeptidases. Malaria is the world's most prevalent parasitic disease. Due to the rapid spread of drug resistant parasites there is a need to develop new antimalarial drugs. In this proposal we will characterise new targets and novel methods of inhibition that will form the basis of a new mechanism for antimalarial drugs.